FHIR © HL7.org  |  Server Home  |  XIG Home  |  Server Source  |  FHIR  

FHIR IG Statistics: FHIR Resources

Resources - All Kinds, Realm US, Authority Hl7

16,284 resources

Type: Text:

By Version

 

Start Prev Rows 6800 - 7000 Next

PackageVersionIdentityName/TitleStatusFMMWGDate
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.115Pathological T Stage T4cactive2024-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.116Pathological T Stage T4bactive2024-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.117Pathological T Stage T4aactive2024-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.118Pathological T Stage T4active2024-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.120N Stage N2Cactive2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.121T Stage T3cactive2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.122T Stage T3bactive2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.123T Stage T3aactive2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.124Pathological T Stage T3active2024-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.125T Stage T2cactive2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.126T Stage T2bactive2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.127T Stage T2aactive2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.128Pathological T Stage T2active2024-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.129Pathological T Stage T1cactive2024-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.132Pathological T Stage T1bactive2024-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.135Pathological T Stage T1aactive2024-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.136Pathological T Stage T1active2024-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.137Pathological T Stage T1micactive2024-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.139Pathological T Stage T0active2024-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.142Cancer Stage IIIactive2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.143Cancer Stage IIIAactive2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.144Cancer Stage IIIBactive2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.145Cancer Stage IIICactive2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.146Cancer Stage IVactive2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.147Cancer Stage IVAactive2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.148Cancer Stage IVBactive2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.149Cancer Stage IVCactive2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.151Cisplatin Injectableactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.153Vinorelbine Injectableactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.154Gemcitabine Injectableactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.155Docetaxelactive2024-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.156Pemetrexed Injectableactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.158Vinblastine Injectableactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.160ECOG Performance Statusactive2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.161ECOG Performance Statusactive2020-10
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.162ECOG Performance Statusactive2022-03
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.164Karnofsky Performance Statusactive2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.165Carboplatin Injectableactive2020-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.166Paclitaxelactive2024-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.168Doxorubicin Injectableactive2022-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.169Irinotecan Injectableactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.179Bevacizumab Injectableactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.181Methotrexateactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.184Breast Canceractive2022-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.185Breast Canceractive2023-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.191Cancer Stage IIactive2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.192Cancer Stage IIAactive2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.193Cancer Stage IIBactive2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.194Pertuzumab Injectableactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.196Ixabepilone Injectableactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.197Goserelinactive2024-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.200Epirubicin Injectableactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.202Ramucirumab Injectableactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.204Letrozoleactive2024-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.206Exemestaneactive2024-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.209Fluorouracilactive2024-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.210Capecitabine Oralactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.222Aprepitant Oralactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.223Fosaprepitant Injectableactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.255Colorectal Canceractive2021-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.256Colorectal Canceractive2021-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.257Colorectal Cancer Chemotherapyactive2023-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.280Cancer Stage IAactive2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.281Cancer Stage IBactive2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.286Cancer Stage IICactive2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.291Positive Resultactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.292Negative Resultactive2015-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.300Pathological N Stage N1Cactive2024-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.332Daunorubicin Injectableactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.336Palonosetron Injectableactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.341External Beam Radiotherapyactive2024-04
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.349Metastatic Canceractive2023-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.439T Categoryactive2018-05
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.440N Categoryactive2018-05
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.441M Categoryactive2018-05
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.442TNM Stage Groupactive2018-05
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.449Opioidsactive2024-03
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.492Pharmacological interventions for depressionactive2024-05
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.535Ovarian Canceractive2023-05
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.536Ovarian Canceractive2023-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.537Fallopian Tube Canceractive2022-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.539Fallopian Tube Canceractive2022-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.541Peritoneal Canceractive2022-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.542Peritoneal Canceractive2023-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.547Cancer Stage 1Cactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.555Gender Femaleactive2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.556Gender Maleactive2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.557Pathological N Stage N3aactive2024-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.558Pathological N Stage N3bactive2024-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.560Rolapitant Oralactive2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.599Obinutuzumab Injectableactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.600Ofatumumab Injectableactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.602Neurokinin 1 Receptor Antagonistactive2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.604Serotonin Receptor Antagonistactive2025-04
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.61Cetuximab Injectableactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.63Panitumumab Injectableactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.81Palonosetron Oralactive2024-12
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.88Lung Canceractive2015-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.89Lung Canceractive2023-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.95M Stage M0active2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.97Pathological M Stage M1active2024-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.98Pathological M Stage M1aactive2024-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1116.99Pathological M Stage M1bactive2024-08
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1125.7PROMIS Depression Assessmentactive2023-05
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.11Sleep Apneaactive2018-05
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.13Septic Shock due to C. Diffactive2019-04
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.15Body Temperatureactive2022-03
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.16Diarrhea Potentially due to CDIactive2019-04
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.17Abdominal Distensionactive2019-04
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.18Vomiting potentially due to CDIactive2019-04
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.19Ileus due to infectionactive2019-04
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.20Clostridium difficile infectionactive2019-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.3Radiation Therapy Indicators from CPTactive2017-03
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.4Diagnostic Radiology Surrounding Face and Sinusactive2017-03
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.5Ear Surgery Affecting the Tympanic Membraneactive2017-03
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.6Allergic Rhinitis Immunotherapyactive2017-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.8Radiology to Head and Sinusactive2017-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1130.9Immunotherapy For Allergic Rhinitisactive2022-03
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1136.63Aortic Dissection or Ruptured Aortic Aneurysmactive2024-07
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.1C2S Alcohol Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.11C2S Amphetamine Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.12C2S Cannabis Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.13C2S Cannabis Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.14C2S Cannabis Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.15C2S Cannabis Use DIsordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.16C2S Cocaine Use Disorderactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.17C2S Cocaine Use Disorderactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.18C2S Cocaine Use Disorderactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.19C2S Hallucinogensactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.2C2S Alcohol Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.20C2S Hallucinogensactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.21C2S Hallucinogensactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.22C2S Hallucinogensactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.23C2S HIV/AIDS Information Sensitivityactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.24C2S HIV/AIDS Information Sensitivityactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.25C2S HIV/AIDS Information Sensitivityactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.26C2S HIV/AIDS Information Sensitivityactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.27C2S HIV/AIDS Information Sensitivityactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.28C2S Inhalantsactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.29C2S Inhalantsactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.3C2S Alcohol Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.30C2S Inhalantsactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.32C2S Mental Health Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.33C2S Mental Health Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.34C2S Mental Health Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.35C2S Mental Health Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.36C2S Mental Health Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.38C2S Opioidsactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.39C2S Opioidsactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.4C2S Alcohol Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.40C2S Opioidsactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.42C2S Opioidsactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.43C2S Other Psychoactive Substance Use Disorderactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.44C2S Other Psychoactive Substance Use Disorderactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.45C2S Other Psychoactive Substance Use Disorderactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.46C2S Sedative Hypnotic, or anxiolytic related disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.47C2S Sedative Hypnotic, or anxiolytic related disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.48C2S Sedative Hypnotic, or anxiolytic related disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.49C2S Sexuality and reproductive health information sensitivityactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.5C2S Alcohol Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.51C2S Tobacco Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.52C2S Tobacco Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.53C2S Tobacco Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.54C2S Tobacco Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.55C2S Substance Use Information Sensitivityactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.56C2S Substance Use Information Sensitivityactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.58C2S Sensitive Categoriesactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.59C2S Opioidsactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.6C2S Amphetamine Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.60C2S HIV/AIDS information Sensitivityactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.65Test C2S Alcohol Use Disordersactive2019-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.67Test C2S HIV/AIDS Information Sensitivityactive2019-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.7C2S Amphetamine Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.8C2S Amphetamine Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1142.9C2S Amphetamine Use Disordersactive2016-09
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.10Diphtheria (Tests for Corynebacterium diphtheriae by Culture and Identification Method)active2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1002Tuberculosis (Tests for Mycobacterium species by Culture and Identification Method)active2023-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1012S. Typhi Infection (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1016S. Paratyphi Infection (Disorders) (SNOMED)active2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1017S. Typhi Infection (Tests for S. Typhi by Culture and Identification Method)active2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1021Dark Urine (SNOMED)active2023-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1022Acute Onset [Qualifier Value] (SNOMED)active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1024Acute Viral Hepatitis (SNOMED)active2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1027Sepsis [Septicemia] [Bacterial] [Unspecified Organism] (ICD10CM)active2023-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1029Listeriosis [Listeria species] (Organism or Substance in Lab Results)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1030Meningitis [Unspecified Cause] (ICD10CM)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1032Encephalitis [Unspecified Cause] (ICD10CM)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1033Encephalitis [Unspecified Cause] (SNOMED)active2023-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1035Indeterminate or Equivocal Lab Result Valueactive2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1037Smoking Status [Current Nonsmoker] (SNOMED)active2024-06
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1040Organisms (Tests by Unspecified Method)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1041Organisms (Tests by Culture and Identification)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1044Candida auris Infection (Tests for Candida auris by Culture and Identification Method)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1045Candida auris Infection (Tests for Candida auris Nucleic Acid)active2023-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1047Parkinson’s disease (Disorders) (ICD10CM)active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1048Parkinson’s disease (Disorders) (SNOMED)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1049Parkinsonism [Secondary] (ICD10CM)active2024-01
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1050Parkinsonism [Secondary] (SNOMED)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1065Consciousness [Decreased Level] (SNOMED)active2025-02
us.nlm.vsacR4ValueSet/2.16.840.1.113762.1.4.1146.1071Drug Use [IV Evidence] (SNOMED)active2023-01